Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	Related Studies

Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

This study is currently recruiting participants.
Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00410462

Locations


Netherlands
	Leiden University Medical Center	Recruiting
	Leiden, Netherlands, 2300 RC
	Contact: Hans Gelderblom, MD, PhD 31-71-526-3486

Sponsors and Collaborators

European Organization for Research and Treatment of Cancer

Investigators


Study Chair:	Hans Gelderblom, MD, PhD	Leiden University Medical Center